Clinical trial NCT05798208: Effect of Covid-19 on Hypertension
Official title: The Long-term Impact of COVID-19 on Blood Pressure: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Hypertension
Keywords: covid-19
hypertension
blood pressure
Lead sponsor: Shiraz University of Medical Sciences
Sponsor class: OTHER
First posted: 2023-04-04
Enrollment: 5355
Sex: ALL
Minimum age (years): 39
Maximum age (years): 71
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Covid patients with recorded blood pressure before and after covid infection

Brief summary: In this single center , retrospective study, 5355 covid patient were selected from 2020 to 2022, with recorded blood pressure before covid and recording after covid. Blood pressure before and after covid were compared, by pair T test.

Detailed description: design and participants This single-center retrospective cohort study was conducted at an outpatient cardiology clinic in Shiraz, Iran, between February 15, 2020, and December 28, 2022. We evaluated patients with a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA reverse-transcriptase polymerase-chain-reaction assays from nasopharyngeal or oropharyngeal swab specimens according to World Health Organization guidelines (12). Two physicians (PA, MY) reviewed the patients' electronic medical records, including demographics, comorbidities, vital signs, treatments, and outcomes. Ambiguities were resolved by a third author (MM).

The current study included all COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery. The following patients were excluded: those under 18, with hospital admission due to COVID-19, who received corticosteroid therapy, those with a history of systemic inflammatory disease, kidney or liver, immunocompromised patients, and those who switched their antihypertensive regimen during the study. Finally, 5,355 eligible patients were investigated . The primary outcome was to assess BP variation following infection (particularly a prolonged rise in BP) among non-hospitalized COVID-19 patients. The secondary outcome was to identify the predictor factors of BP variation.

The present study was approved by the Ethics Committee of Shiraz University of Medical Sciences under code IR.SUMS.MED.REC.1401.465 , and the need for informed consent was waived due to the study's retrospective nature and the absence of patient identifiers in the presented data.

Eligibility criteria: Inclusion Criteria:

* All COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery

Exclusion Criteria:

* Age under 18
* Hospital admission due to COVID-19
* Corticosteroid therapy,
* History of systemic inflammatory disease
* kidney disease
* liver disease
* Immunocompromised patients

Primary outcomes:
measure: change of blood pressure
timeFrame: 2 years
Secondary outcomes:
measure: predictors of changes in blood pressure
timeFrame: 2 years
Other outcomes:
Locations:
city: Shiraz
country: Iran, Islamic Republic of
facility: Cardiology Ward Shiraz University of Medical Sciences
state: Fars
city: Shiraz
country: Iran, Islamic Republic of
facility: Education Developmen Center
state: Fars
city: Shiraz
country: Iran, Islamic Republic of
facility: Professor kojuri cardiology clinic
state: Outside Of The US
Study officials:
References: